Pablo J. Cagnoni
Pharmaceutics
MPM Capital
Hungary
Biography
Pablo Cagnoni, M.D., is President and CEO of Tizona. Over of the course of his career as an oncologist and pharmaceutical executive, Pablo has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases. He has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto® Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among them.
Research Interest
Antigen Processing and Presentation, Cellular Adhesion, Migration, and Inflammation, Hematopoiesis and Immune System Development, Mucosal and Regional Immunology, Veterinary and Comparative Immunology
